US Secondary Hyperparathyroidism Treatment(SHPT) Market

US Secondary Hyperparathyroidism Treatment (SHPT) Market Size, Share, Growth Analysis, By Drug Analysis(hospital & retail pharmacies, online channel, and other), By Region - Industry Forecast 2024-2031


Report ID: SQMIC35J2108 | Region: Country | Published Date: February, 2024
Pages: 157 | Tables: 36 | Figures: 74

US Secondary Hyperparathyroidism Treatment (SHPT) Market Insights

US Secondary Hyperparathyroidism Treatment (SHPT) Market size was valued at USD 4.59 billion in 2019 and is poised to grow from USD 5 billion in 2023 to USD 9.97 billion by 2031, growing at a CAGR of 9% in the forecast period (2024-2031).

Secondary hyperparathyroidism is characterized by the sustained rises in levels of biochemical indicators of mineral metabolism that lead to the release of excessive amounts of parathyroid hormone (SHPT). It affects persons with chronic kidney disease (CKD) and those who need renal replacement therapy. The Centers for Disease Control and Prevention (CDC) currently projects that 37 million Americans, or about 15% of adult Americans, have CKD. Furthermore, CKD is reported to be more prevalent in those 65 years of age and older than in those 45 to 64 years of age. Rising patient numbers are correlated with rising treatment costs for secondary hyperparathyroidism.

Although medications are frequently provided for SHPT, surgery is advised in difficult cases when the thyroid glands release excessive amounts of PTH. Although surgical procedures have demonstrated improved treatment accuracy, they are less preferred due to their expensive cost and the market's accessibility to efficient medications. The U.S. Medicare national insurance programme covers medications for SHPT. Medication for the treatment of SHPT was just added to the Part B package of Medicare Insurance in January 2018. In the United States, there are numerous nonprofit organizations that support patients who are uninsured or have inadequate insurance, significantly lowering the cost of SHPT treatment for everyone. Despite the fact that the government provides health insurance through public programmes, people still have significant out-of-pocket costs.

US Secondary Hyperparathyroidism Treatment (SHPT) Market is poised to grow at a sustainable CAGR for the next forecast period.

$3,500
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

US Secondary Hyperparathyroidism Treatment (SHPT) Market size was valued at USD 4.59 billion in 2019 and is poised to grow from USD 5 billion in 2023 to USD 9.97 billion by 2031, growing at a CAGR of 9% in the forecast period (2024-2031).

Amgen Inc. holds 40% of the US secondary hyperparathyroidism therapy (SHPT) market thanks to its substantial strategic decisions and robust pharmaceutical portfolio. SHPT is treated with Sensipar (Cinacalcet), a well-liked medication from Amgen. Generic manufacturers have only recently begun to enter the market as a result of numerous treatments' expiration of their patents. Organizations like Teva Pharmaceutical Industries Ltd., Abbvie, and Sandoz are among the market players. SHPT market expansion is also anticipated to be fueled by expanding generic manufacturer competition during the anticipated time frame. ' Amgen Inc. ', ' Sanofi S.A. ', ' F. Hoffmann-La Roche Ltd ', ' AbbVie Inc. ', ' Pfizer Inc. ', ' Bayer AG ', ' AstraZeneca Plc ', ' Eli Lilly and Company ', ' Johnson & Johnson ', ' Teva Pharmaceutical Industries Ltd. ', ' Novartis AG ', ' GlaxoSmithKline Plc ', ' Merck & Co., Inc. ', ' Bristol-Myers Squibb Company ', ' Takeda Pharmaceutical Company Ltd. ', ' Boehringer Ingelheim International GmbH ', ' Daiichi Sankyo Company, Limited ', ' Astellas Pharma Inc. ', ' Ipsen Biopharmaceuticals, Inc. ', ' Mallinckrodt Pharmaceuticals '

SHPT development occurs simultaneously with vitamin D deficiency. Over 97% of ESRD patients, according to OPKO Health, Inc., show signs of vitamin D deficiency, which is a key sign that SHPT is developing in the patient. As a result, it is anticipated that the increase in the number of chronic illnesses brought on by sedentary lifestyles will drive the SHPT treatment market in the United States. The secondary hyperparathyroidism (SHPT) treatment market in the United States is also significantly influenced by the government's initiative to develop standards for better treatment management. The control of biochemical indicators of mineral and bone metabolism, which have a strong epidemiologic connection to cardiovascular events and bone fractures, is the goal of SHPT therapy.

As medical professionals and clinical specialists have become more aware of the condition, the management plan for SHPT has been improved.The growth of the market for treatments for CKD and ESRD would benefit from the early detection and evaluation of secondary hyperparathyroidism for mineral metabolism. The market is expected to grow more quickly during the projection period because there will be fewer issues with SHPT management.

Geographically, the West, Midwest, South, and Northeast areas make up the U.S. SHPT therapy market. The South region brought in USD 1.93 billion in revenue and is expected to take the lead in the US market over the next several years. The South region's dominance can be attributed to the existence of a large number of dialysis facilities and the strategic positioning of top dialysis clinic networks like Fresenius Care, DaVita, etc. in the area. Additionally, due to the high incidence of older people with kidney disorders, the southern region of the United States has the highest prevalence of secondary hyperparathyroidism.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

US Secondary Hyperparathyroidism Treatment(SHPT) Market

Report ID: SQMIC35J2108

$3,500
BUY NOW GET FREE SAMPLE